Centessa appoints John Crowley as CFO, Gregory Weinhoff as Chief Business Officer

Centessa Pharmaceuticals plc

John Crowley appointed CFO effective June 10, 2024; replaces Gregory Weinhoff who becomes CBO.
Crowley receives $525k base salary, 40% target annual bonus, and option to purchase 600,000 ADSs.
Crowley previously CFO of Fusion Pharmaceuticals (acquired by AstraZeneca) and Merus, plus finance roles at Charles River, Ironwood, Vertex.
Weinhoff moves from CFO to newly created CBO role; he co-founded Arvelle Therapeutics and led in-licensing of cenobamate.
No family relationships or related-party transactions disclosed between Crowley and the company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Crowley

Chief Financial Officer

CNTA · Centessa Pharmaceuticals plc

Effective: 2024-06-10
Filed: June 10, 2024, 7:59 PM ET

On June 10, 2024, Centessa Pharmaceuticals plc (the “Company”) announced the appointment of John Crowley as Chief Financial Officer, which was approved by the Board of Directors of the Company on June 5, 2024, effective June 10, 2024 (the “Start Date”).

Role change

Gregory Weinhoff

Chief Business Officer

CNTA · Centessa Pharmaceuticals plc

Effective: 2024-06-10
Successor: John Crowley
Filed: June 10, 2024, 7:59 PM ET

On June 10, 2024, the Company also announced that the Board has appointed Dr. Gregory Weinhoff as the Company’s Chief Business Officer, on June 5, 2024, effective on the Start Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Crowley was appointed as Chief Financial Officer at Centessa Pharmaceuticals plc.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 10, 2024, Centessa Pharmaceuticals plc (the “Company”) announced the appointment of John Crowley as Chief Financial Officer, which was approved by the Board of Directors of the Company on June 5, 2024, effective June 10, 2024 (the “Start Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Gregory Weinhoff was appointed as Chief Business Officer at Centessa Pharmaceuticals plc.

Action: appointed
Role: Chief Business Officer

Exact text from the filing

On June 10, 2024, the Company also announced that the Board has appointed Dr. Gregory Weinhoff as the Company’s Chief Business Officer, on June 5, 2024, effective on the Start Date.

View on SEC.gov

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001193125-24-157839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.